Introduction
============

Among the three *BCR-ABL1*-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia and primary myelofibrosis (PMF), the latter is by far the worst in terms of both survival and quality of life.^[@bib1],\ [@bib2]^ The more aggressive disease biology in PMF is also manifest by the higher prevalence of cytogenetic abnormalities^[@bib3]^ and somatic mutations.^[@bib4]^ The latter involve *JAK2*, *MPL*, *TET2*, *ASXL1*, *CBL*, isocitrate dehydrogenase (*IDH*)*1*, *IDH2*, *IKZF1*, *LNK*, *EZH2* and *DNMT3A*.^[@bib4],\ [@bib5]^ Recent studies have reported higher frequencies of *IDH1/IDH2* and *LNK* mutations in blast-phase MPN,^[@bib6],\ [@bib7]^ suggesting a pathogenetic contribution to disease progression.

Isocitrate dehydrogenase-1 is located on chromosome 2q33.3 and *IDH2* on chromosome 15q26.1. Both genes encode enzymes that catalyze oxidative decarboxylation of isocitrate to α-ketoglutarate. *IDH* mutations involve exon 4 and affect three specific arginine residues: R132 (*IDH1*), R172 (*IDH2*) and R140 (*IDH2*).^[@bib8]^ The mutant *IDH* has decreased affinity for isocitrate but displays catalytic activity in converting α-ketoglutarate to 2-hydroxyglutarate.^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ Decreased supply of α-ketoglutarate or accumulation of 2-hydroxyglutarate is believed to underlie the oncogenic properties of the mutant *IDH*.^[@bib9],\ [@bib13]^

*IDH* mutations are prevalent in low-grade gliomas and secondary glioblastomas (mutational frequency ∼70%)^[@bib14]^ and they have also been described, although at a much lower frequency, in myeloid malignancies including acute myeloid leukemia (AML; 10--20%),^[@bib15],\ [@bib16],\ [@bib17],\ [@bib18]^ myelodysplastic syndrome (MDS; 3--5%),^[@bib19],\ [@bib20]^ MPN (1--4%),^[@bib8],\ [@bib18]^ MDS/MPN including chronic myelomonocytic leukemia (∼9%),^[@bib20]^ post-MDS AML (∼15%),^[@bib19]^ post-MPN AML (∼22%),^[@bib8]^ post-MDS/MPN AML (∼10%),^[@bib20]^ del(5q)-associated high-risk MDS or AML (∼22%)^[@bib21]^ and blast-phase chronic myelogenous leukemia (∼4%).^[@bib22]^ Single case reports also included angioimmunoblastic lymphoma^[@bib23]^ and acute lymphoblastic leukemia.^[@bib18]^

Several studies have examined the phenotypic and prognostic effects of both *IDH1* and *IDH2* mutations in AML, and most have shown a consistent association with normal or intermediate-risk karyotype, sole trisomy 8 and *NPM1* mutations.^[@bib16],\ [@bib17],\ [@bib23],\ [@bib24],\ [@bib25],\ [@bib26],\ [@bib27]^ The mutant *IDH1* was associated with worse prognosis in cytogenetically normal AML with *NPM1*^+^/*FLT3*^−^ molecular profile^[@bib17],\ [@bib28],\ [@bib29]^ and better prognosis in *FLT3*^+^ AML.^[@bib27]^ In some^[@bib17]^ but not other^[@bib30]^ studies, the mutant *IDH2* was associated with unfavorable prognosis in cytogenetically normal AML,^[@bib17]^ whereas a more recent study suggested that the mutant *IDH2*R140 was prognostically more favorable than the mutant *IDH2*R172.^[@bib31]^

Unlike the case with AML, there is limited information on the prognostic impact of *IDH* mutations in chronic myeloid neoplasms, including MDS^[@bib19]^ and MPN.^[@bib8]^ We recently reported on *IDH1* and *IDH2* mutational frequencies among 1473 patients with *BCR-ABL1*-negative MPN:^[@bib8]^ 0.8% in essential thrombocythemia, 1.9% in polycythemia vera, 4.1% in PMF, 1% in post-essential thrombocythemia/polycythemia vera MF, 0% in blast-phase essential thrombocythemia, 25% in blast-phase polycythemia vera and 25% in blast-phase PMF. The particular study included only 111 patients with chronic-phase PMF and complete clinical information; therefore, detailed prognostic analysis was limited, especially in terms of clinically relevant mutation interactions. In the current study, we examined the phenotypic and prognostic effects of *IDH1* and *IDH2* mutations among 301 patients with chronic-phase PMF, in the context of other MPN-associated mutations.

Materials and methods
=====================

This study was approved by the Mayo Clinic Institutional Review Board. All patients provided informed written consent for study sample collection and permission for use in research. Study eligibility criteria included availability of bone marrow histology and cytogenetic information at the time of referral to the Mayo Clinic. The diagnoses of PMF and leukemic transformation were according to the World Health Organization criteria.^[@bib32]^ Patients with blast-phase disease at the time of their referral to the Mayo Clinic were excluded from the study because one of the objectives of the study was to assess mutation impact on leukemic transformation. Unfavorable karyotype designation and DIPSS-plus (Dynamic International Prognostic Scoring System-plus) risk categorization were as described previously.^[@bib33],\ [@bib34]^ All study patients were fully characterized for karyotype, *JAK2* and *MPL* mutational status and DIPSS-plus risk category.

DNA from bone marrow or peripheral blood was extracted using conventional methods. *MPL* and *JAK2* mutation analyses were performed according to previously published methods.^[@bib35],\ [@bib36],\ [@bib37],\ [@bib38]^ *IDH1* and *IDH2* mutations were analyzed by direct sequencing and/or high-resolution melting assay. Direct sequencing for *IDH1* exon 4 mutations was performed using the following primer sequences: sense, 5′-CGGTCTTCAGAGAAGCCATT-3′ and anti-sense, 5′-CACATTATTGCCAACATGAC-3′.^[@bib18]^ *IDH2* exon 4 was amplified using sense, 5′-CCACTATTATCTCTGTCCTC-3′ and anti-sense, 5′-GCTAGGCGAGGAGCTCCAGT-3′.^[@bib19]^ Both reactions were performed in 25 μl volume containing 100 ng of DNA, 0.25 Units Taq polymerase, 0.3 m each of dATP, dCTP, dGTP and dTTP, 5 μl of a 10 × PCR Buffer (Roche Diagnostics, Indianapolis, IN, USA) and 0.2 μ each of sense and anti-sense primers. The reaction was denatured at 94 °C for 3 min, followed by 35 cycles of denaturing at 94 °C for 30 s, annealing at 57 °C for 30 s and extension at 72 °C for 40 s. After a final extension at 72 °C for 2 min, the products were confirmed by 1.3% agarose gel and purified using Qiagen\'s PCR quick purification kit (Qiagen, Santa Clarita, CA, USA). The product was sequenced using the ABI PRISM 3730xl analyzer (Applied Biosystems Inc., Foster City, CA, USA) to screen for the presence of mutations.

High-resolution melting was performed using the LightCycler 480 Real-Time PCR system (Roche Diagnostics), using the above-mentioned primers for *IDH1* mutations (R130) and the following primers for *IDH2* mutations (R140 and R172): R140 sense, 5′-GCTGAAGAAGATGTGGAA-3′ and anti-sense, 5′-TGATGGGCTCCCGGAAGA-3′ R172 sense, 5′-CCAAGCCCATCACCATTG-3′ and anti-sense, 5′-CCCAGGTCAGTGGATCCC-3′.

All statistical analyses considered clinical and laboratory parameters obtained at the time of first referral to the Mayo Clinic, which in most instances coincided with the time of bone marrow biopsy at the Mayo Clinic and study sample collection. Differences in the distribution of continuous variables between categories were analyzed by either the Mann--Whitney (for comparison of two groups) or the Kruskal--Wallis (comparison of three or more groups) test. Patient groups with nominal variables were compared by the *χ*^2^-test. Overall survival (OS) was calculated from the date of first referral to the date of death (uncensored) or last contact (censored). Leukemia-free survival (LFS) was calculated from the date of first referral to the date of leukemic transformation (uncensored) or death/last contact (censored). OS and LFS curves were prepared by the Kaplan--Meier method and compared by the log-rank test. Cox\'s proportional hazard regression model was used for multivariable analysis. *P*-values \<l0.05 were considered significant. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all calculations.

Results
=======

A total of 301 consecutive patients with PMF were included in this study. The median age at the time of study was 63 years (range, 14--82) and 65% were males. DIPSS-plus risk distribution was 11% low, 16% intermediate-1, 36% intermediate-2 and 37% high. Other clinical and laboratory characteristics at the time of Mayo Clinic referral are outlined in [Table 1](#tbl1){ref-type="table"}; 40 (13%) patients had received cytoreductive therapy at the time of their first referral at our institution. The study population included 178 patients who were evaluated at or near the time of their diagnosis and their presenting characteristics are separately outlined in [Table 2](#tbl2){ref-type="table"}.

The mutant *IDH* was detected in 12 patients (4%): 7 *IDH2* (5 R140Q, 1 R140W and 1 R172G) and 5 *IDH1* (3 R132S and 2 R132C). *MPL* exon 10 was mutated in 18 patients (6.3%) and constituted W515L in 14 patients, W515K in 3 and a novel frameshift mutation in 1 patient. *JAK2*V617F was detected in 169 (56%) patients. Six patients displayed both *JAK2*V617F and *IDH* mutations (*IDH2*R140Q in two patients, *IDH2*R140W in one and *IDH1*R132S in three); *JAK2*V617F allele burdens in these six patients with concomitant mutant *IDH* were 1, 7, 22, 27, 30 and 96%, respectively. One patient displayed both *IDH*R140Q and *MPL*W515R. In all, 107 (36%) patients were negative for all three mutations (that is, *JAK2*V617F, *MPL* exon 10 and *IDH1/2*).

The 12 *IDH*-mutated patients, with or without concomitant *JAK2*V617F, were clinically compared with patients belonging to the 3 other molecular subgroups: mutated for *JAK2* only (*n*=164), mutated for *MPL* only (*n*=18) and unmutated for all three (*n*=107). As can be seen in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, the four molecular subgroups were remarkably similar in their phenotype with few exceptions; *IDH*-mutated patients were significantly older than those with no mutations (*P*=0.04), whereas age distribution was similar between patients with mutant *IDH*, *MPL* or *JAK2*. At the time of this writing, 192 (64%) deaths and 36 (12%) leukemic transformations were documented. The median follow-up time for living patients was 68 months (range 12--296). Treatment over the course of the disease was primarily with conventional drugs, and a total of 53 therapeutic splenectomies and 24 transplants were documented.

In univariate analysis, *IDH*-mutated patients lived shorter than did those with *JAK2* (*P*=0.03), *MPL* (*P*=0.047) or no mutations (*P*=0.0009). The OS data for the four molecular subgroups are shown in [Figure 1](#fig1){ref-type="fig"}. *IDH*-mutated patients also showed significantly shorter LFS, compared with those with *JAK2* (*P*=0.0008), *MPL* (*P*=0.02) or no mutations (*P*=0.001), as shown in [Figure 2](#fig2){ref-type="fig"}. LFS was similar between patients with no mutations and those with either *MPL* (*P*=0.47) or *JAK2* (*P*=0.99). The OS of patients with no mutations was significantly longer than those with *JAK2*V617F (*P*=0.01), but not than those with *MPL* mutations (*P*=0.41). After accounting for age, the OS difference between patients with *JAK2*V617F and no mutations became insignificant (*P*=0.40), whereas the presence of the mutant *IDH* remained a significant disadvantage for both OS (*P*=0.04) and LFS (*P*=0.005).

Multivariable analysis of OS that included risk categorization per DIPSS-plus^[@bib33]^ confirmed the independent prognostic relevance of the mutant *IDH* (*P*=0.03): hazard ratio (HR) for patients with no mutations=0.39, 95% confidence interval (95% CI) 0.2--0.75; HR for *JAK2*-mutated patients=0.50, 95% CI, 0.27--0.95; HR for *MPL*-mutated patients=0.53, 95% CI, 0.23--1.2. A similar analysis for LFS that included risk factors for leukemic transformation (that is, unfavorable karyotype and platelet count \<100 × 10^9^/l) as covariates also confirmed the prognostic relevance of the mutant *IDH* (*P*=0.003): HR for patients with no mutations=0.16; 95% CI, 0.06--0.46; HR for *JAK2*-mutated patients=0.18; 95% CI, 0.06--0.48; HR for *MPL*-mutated patients=0.09; 95% CI, 0.01--0.76).^[@bib33]^ Further analysis disclosed that the negative OS ([Figure 3](#fig3){ref-type="fig"}) and LFS ([Figure 4](#fig4){ref-type="fig"}) effect of the mutant *IDH* was most pronounced in the presence (*P*=0.0002 and *P*\<0.0001, respectively) as opposed to the absence (*P*=0.34 and *P*=0.64, respectively) of concomitant *JAK2*V617F expression. Analysis of paired samples obtained during the chronic and blast phases of the disease was possible in two *IDH*-mutated patients and showed the presence of both *IDH* and *JAK2* mutations at both time points.

Discussion
==========

The most feared disease complication in MPN is leukemic transformation.^[@bib39]^ In PMF, risk factors for leukemic progression include unfavorable karyotype,^[@bib3]^ thrombocytopenia (platelet count \<100 × 10^9^/l) and ⩾3% circulating blasts;^[@bib33],\ [@bib40]^ the 10-year incidence of AML was estimated at 12% in the absence of unfavorable karyotype and thrombocytopenia and 31% in the presence of either one of the two risk factors.^[@bib33]^ Prognosis in post-PMF AML is dismal with a median survival of \<3 months and is not favorably affected by conventional chemotherapy.^[@bib39]^ The discovery of *JAK2*V617F in the majority of patients with PMF raised hopes of better outcome with effective molecularly targeted therapy.^[@bib41]^ However, it has since been realized that the presence or absence of *JAK2*V617F in PMF did not affect leukemic transformation^[@bib35]^ and that leukemic blasts in *JAK2*-mutated patients who develop AML did not necessarily express the mutation.^[@bib42]^ These observations suggest that *JAK2*V617F is neither necessary nor sufficient for leukemic progression in PMF.

This study suggests that the presence of the mutant *IDH* signifies an increased risk of leukemic transformation in PMF and also raises the intriguing possibility of leukemogenic collaboration between the mutant *IDH* and *JAK2*V617F; 4 (67%) of 6 patients with concomitant *IDH* and *JAK2* mutations developed AML as opposed to only 1 (17%) of 6 *IDH*-mutated patients without concomitant *JAK2*V617F, 1 (6%) of 18 with *MPL* mutations, 17 (10%) of 164 with only *JAK2* mutation and 13 (12%) of 107 patients with no mutations (*P*\<0.0001; [Figure 4](#fig4){ref-type="fig"}). A similar clinical observation was made in a recent report that showed an inferior LFS in *IDH*-mutated myeloid malignancies with isolated del(5q);^[@bib43]^ in the particular study, two of six patients with *IDH* mutations also carried *JAK2*V617F and both had transformed into AML, whereas only two of the remaining four *IDH*-mutated patients without concomitant *JAK2*V617F had transformed into AML.^[@bib43]^ The possibility that the mutant *IDH* collaborates with other oncogenes is further supported by a recent report in which the mutant *IDH* enhanced growth and mitogen-activated protein kinase and signal transducer and activator of transcription-3 signaling in *BRAF*-mutated melanoma cells.^[@bib44]^

Currently known mutations in PMF are believed to represent late genetic events derived from an ancestral abnormal clone the genetic make up of which remains elusive. The fact that many of these mutations are infrequent and lack disease specificity further undermines their pathogenetic contribution to disease initiation.^[@bib4]^ On the other hand, the absence of mutual exclusivity and the higher prevalence of some MPN-associated mutations (for example, *IDH*,^[@bib6]^ *LNK*,^[@bib7]^ *IKZF1*^[@bib45]^ and *TP53*^[@bib46]^ mutations) in blast-phase, as opposed to chronic-phase, disease suggests possible pathogenetic contribution to leukemic transformation. The observations from this study suggest one possibility in which mutations with non-redundant functional consequences collaborate to amplify the development of AML. Alternatively, the presence of mutations of interest (such as the mutant *IDH*) in at-risk patients might simply constitute a marker of genomic instability associated with impending leukemic transformation. A third possibility considers the distribution of specific mutations in independent clones that arise from a common ancestral clone that is susceptible to both emergence of mutations of interest and leukemic transformation.^[@bib47]^

The prognostic impact of *IDH* mutations in AML has been studied extensively.^[@bib16],\ [@bib17],\ [@bib23],\ [@bib24],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28],\ [@bib29],\ [@bib30]^ In contrast, very few studies have looked into this matter in chronic myeloid malignancies. Both *IDH1* and *IDH2* mutations occur in MDS, although some studies^[@bib19]^ have reported a preponderance of *IDH1* mutations, whereas others have shown the opposite.^[@bib20]^ In the current PMF study, 7 of the 12 *IDH* mutations involved *IDH2*. In MDS and other myeloid neoplasms associated with sole del(5q), the presence of mutant *IDH* has been associated with inferior OS and LFS.^[@bib19],\ [@bib21],\ [@bib43]^ It is noteworthy that the MDS study showing a detrimental prognostic effect of the mutant *IDH* involved only *IDH1* mutations.^[@bib19]^ In this study, there was no evidence to suggest that *IDH1* and *IDH2* mutations were prognostically different (data not shown). Regardless, the number of cases with *IDH* mutations in this study (*n*=12) was too small to accurately determine the individual prognostic contribution of *IDH1* vs *IDH2* mutations in PMF.

*JAK2*V617F in PMF and other MPN is associated with advanced age.^[@bib48]^ This study suggests that *IDH* mutations in PMF also cluster with older age. A similar observation has been made in AML as well^[@bib28]^ and underscores the importance of accounting for age in evaluating the prognostic significance of *IDH* mutations. Another characteristic feature of *IDH*-mutated PMF in this study was the relative paucity of abnormal or unfavorable karyotype. This particular observation has also been noted in the context of AML, MDS, MDS/MPN and post-MDS/MPN AML^[@bib8],\ [@bib18],\ [@bib20]^ and suggests that *IDH* mutations are not simply markers of genomic instability.

Our clinical observations underscore the potential relevance of looking for other mutations or epigenetic abnormalities that functionally mimic the mutant *IDH*, in *JAK2*-mutated PMF.^[@bib13]^ It would also be interesting to examine the mutant *IDH*-induced phenotypic modifications of *JAK2*V617F mouse models. Whether therapeutic targeting of the mutant *IDH* or interfering with the production/function of its 'oncogenic\' metabolite (that is, 2-hydroxyglutarate) would favorably affect leukemic progression in PMF remains to be seen.
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###### Comparison of clinical characteristics of patients with primary myelofibrosis stratified by the presence or absence of *IDH*, *MPL* and *JAK2* mutations

  *Variables*                                  *All patients (*n*=301)*   IDH *mutated (*n*=12)*   MPL *mutated (*n*=18)*   JAK2 *mutated (*n*=164)*   IDH/MPL/JAK2 *unmutated (*n*=107)*   P*-value*
  -------------------------------------------- -------------------------- ------------------------ ------------------------ -------------------------- ------------------------------------ ------------
  Age (years); median (range)                  63 (14--82)                66 (50--74)              62 (35--82)              65 (28--81)                58 (14--79)                          **0.0002**
  Age \>65 years; *n* (%)                      96 (32%)                   6 (50%)                  6 (33%)                  77 (47%)                   30 (28%)                             **0.02**
  Males (%)                                    197 (65%)                  7 (58%)                  11 (61%)                 105 (64%)                  74 (69%)                             0.75
  Hemoglobin, g/dl; median (range)             10 (6--15)                 11 (7--15)               10 (6--14)               10 (7--15)                 10 (6--14)                           0.97
  Leukocyte count, × 10^9^/l; median (range)   9 (1--176)                 9 (4--48)                11 (4--50)               10 (1--176)                7 (1--147)                           0.11
  Platelet count, × 10^9^/l; median (range)    222 (11--1493)             141 (66--410)            128 (14--662)            218 (11--984)              257 (13--1493)                       0.06
                                                                                                                                                                                             
  *DIPSS-plus risk group (%)*                                                                                                                                                               
   Low                                         34 (11%)                   0                        4 (22%)                  18 (11%)                   12 (11%)                              
   Intermediate-1                              47 (16%)                   2 (16%)                  2 (11%)                  19 (12%)                   24 (22%)                              
   Intermediate-2                              109 (36%)                  5 (42%)                  3 (17%)                  60 (37%)                   41 (38%)                             0.11
   High                                        111 (37%)                  5 (42%)                  9 (50%)                  67 (41%)                   30 (28%)                              
                                                                                                                                                                                             
  Constitutional symptoms; *n* (%)             115 (38%)                  5 (42%)                  4 (22%)                  69 (42%)                   37 (35%)                             0.30
  Circulating blasts ⩾1% *n* (%)               190 (63%)                  10 (83%)                 11 (61%)                 101 (62%)                  68 (64%)                             0.50
  Hemoglobin \<10 g/dl; *n* (%)                151(50%)                   5 (42%)                  10 (56%)                 88 (54%)                   48 (45%)                             0.46
  Leukocytes \>25 × 10^9^/l; *n* (%)           52 (17%)                   2 (17%)                  4 (22%)                  33 (20%)                   13 (12%)                             0.36
  Platelets \<100 × 10^9^/l; *n* (%)           73 (24%)                   3 (25%)                  8 (44%)                  35 (21%)                   27 (25%)                             0.19
  Leukocytes \<4 × 10^9^/l; *n* (%)            46 (15%)                   1 (8%)                   1 (6%)                   24 (15%)                   20 (19%)                             0.43
  Palpable spleen \>10 cm; *n* (%)             109 (36%)                  2 (17%)                  5 (28%)                  67 (41%)                   35 (33%)                             0.20
  Splenectomy; *n* (%)                         53 (18%)                   2 (17%)                  4 (22%)                  28 (17%)                   19 (18%)                             0.96
                                                                                                                                                                                             
  *Cytogenetic categories*                                                                                                                                                                  
   Normal                                      181 (60%)                  9 (75%)                  12 (67%)                 92 (56%)                   68 (64%)                              
   Favorable                                   89 (30%)                   2 (17%)                  6 (33%)                  53 (32%)                   28 (26%)                             0.55
   Unfavorable                                 31 (10%)                   1 (8%)                   0 (0%)                   19 (12%)                   11 (10%)                              
                                                                                                                                                                                             
  Transplanted; *n* (%)                        24 (8%)                    0 (0%)                   2 (11%)                  10 (6%)                    13 (12%)                             0.31
  Deaths; *n* (%)                              192 (64%)                  11 (92%)                 12 (67%)                 109 (66%)                  58 (54%)                             0.04
  Leukemic transformations; *n* (%)            36 (12%)                   5 (42%)                  1 (6%)                   17 (11%)                   13 (12%)                             0.01

Abbreviation: DIPSS-plus, Dynamic International Prognostic Scoring System-Plus.

Bold values indicate significant differences.

###### Comparison of clinical characteristics of patients with primary myelofibrosis, who were evaluated within 1 year of diagnosis, stratified by the presence or absence of *IDH*, *MPL* and *JAK2* mutations

  *Variables*                                  *All patients (*n*=178)*   IDH *mutated (*n*=10)*   MPL *mutated (*n*=9)*   JAK2 *mutated (*n*=96)*   IDH/MPL/JAK2 *un-mutated (*n*=63)*   P*-value*
  -------------------------------------------- -------------------------- ------------------------ ----------------------- ------------------------- ------------------------------------ -----------
  Age (years); median (range)                  63 (14--81)                66 (50--74)              60 (35--66)             65 (28--81)               58 (14--79)                          **0.005**
  Age \>65 years; *n* (%)                      70 (39%)                   5 (50%)                  1 (11%)                 48 (50%)                  16 (25%)                             **0.004**
  Males (%)                                    116 (65%)                  7 (70%)                  7 (80%)                 63 (66%)                  39 (62%)                             0.79
  Hemoglobin, g/dl; median (range)             10 (6--15)                 11 (7--15)               10 (6--14)              10 (7--15)                11 (6--14)                           0.50
  Leukocyte count, × 10^9^/l; median (range)   8 (1--147)                 10 (4--48)               11 (4--50)              9 (1--99)                 7 (2--147)                           0.15
  Platelet count, × 10^9^/l; median (range)    253 (12--1493)             159 (79--410)            146 (31--662)           245 (12--984)             316 (14--1493)                       0.13
                                                                                                                                                                                           
  *DIPSS-plus risk group (%)*                                                                                                                                                             
   Low                                         25 (14%)                   0                        2 (22%)                 13 (14%)                  10 (16%)                             0.60
   Intermediate-1                              36 (20%)                   2 (20%)                  1 (11%)                 15 (16%)                  18 (29%)                              
   Intermediate-2                              62 (35%)                   4 (40%)                  3 (33%)                 35 (36%)                  20 (32%)                              
   High                                        55(31%)                    4 (40%)                  3 (33%)                 33 (34%)                  15 (24%)                              
                                                                                                                                                                                           
  Constitutional symptoms; *n* (%)             65 (37%)                   4 (40%)                  2 (22%)                 38 (40%)                  21 (33%)                             0.68
  Circulating blasts ⩾1% *n* (%)               101 (57%)                  8 (80%)                  5 (56%)                 54 (56%)                  34(53%)                              0.49
  Hemoglobin \<10 g/dl; *n* (%)                77 (43%)                   4 (40%)                  6 (67%)                 47 (49%)                  20 (32%)                             0.08
  Leukocytes \>25 × 10^9^/l; *n* (%)           26 (15%)                   2 (20%)                  2 (22%)                 14 (15%)                  8 (13%)                              0.84
  Platelets \<100 × 10^9^/l; *n* (%)           36 (20%)                   1 (10%)                  4 (44%)                 17 (18%)                  14 (22%)                             0.22
  Leukocytes \<4 × 10^9^/l; *n* (%)            27 (15%)                   1 (10%)                  1 (11%)                 12 (13%)                  13 (21%)                             0.51
  Palpable spleen \>10 cm; *n* (%)             44 (25%)                   2 (20%)                  2 (22%)                 28 (29%)                  12 (19%)                             0.45
  Splenectomy; *n* (%)                         24 (13%)                   1 (10%)                  3 (33%)                 12 (13%)                  8 (13%)                              0.35
                                                                                                                                                                                           
  *Cytogenetic categories*                                                                                                                                                                
   Normal                                      116 (65%)                  7 (70%)                  6 (67%)                 58 (60%)                  45 (71%)                             0.75
   Favorable                                   48 (27%)                   2 (20%)                  3 (33%)                 30 (31%)                  13 (21%)                              
   Unfavorable                                 14 (8%)                    1 (10%)                  0 (0%)                  8 (8%)                    5 (8%)                                
                                                                                                                                                                                           
  Transplanted; *n* (%)                        15 (8%)                    0 (0%)                   2 (22%)                 5 (5%)                    8 (13%)                              0.12
  Deaths; *n* (%)                              107 (60%)                  9 (90%)                  6 (67%)                 59 (61%)                  32 (51%)                             0.09
  Leukemic transformations; *n* (%)            22 (12%)                   4 (40%)                  1 (11%)                 13 (14%)                  4 (6%)                               0.03

Abbreviation: DIPSS-plus, Dynamic International Prognostic Scoring System-Plus.

Bold values indicate significant differences.
